Inhibikase Therapeutics, Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Operating Expenses
Income Breakdown
Revenue↑+30.8% +$245K
$1M
R&D↓-11.6% -$835K
$6M
SG&A↑+18.1% +$1M
$7M
D&A↓-100.0% -$26K
$0
Operating Income↓-119.1% -$7M
$-13M
EBITDA↓-100.0% -$26K
$0
Interest Expense
—
Tax Provision
$0
Net Income↓-106.5% -$6M
$-12M
Operating Margin
—
Net Margin
—
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)
3.0%
Operating Lease Cost↓-66.7% -$24K
$12K
Revenue YoY Variation↓-79612169.2pts
30.8%
Income YoY Variation↓-96.9pts
-119.1%
Revenue QoQ Variation↑+0.0pts
-100.0%
Income QoQ Variation↓-2.5pts
-17.9%